- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To investigate the effect of a treatment with Imatinib mesylate (Glivec®), Pioglitazone (Actos®), Dexamethasone (Fortecortin®) and Etoricoxib (Arcoxia®) in combination with metronomic chemotherapy (Treosulfane: Ovastat®) on the PSA- response rate in patients with hormone refractory prostate cancer.
Critère d'inclusion
- prostrate carcinoma